Workers Compensation
Medicinal cannabis in personal injury claims is increasingly prescribed, often at high cost, yet largely unapproved and weakly evidenced. Claims teams have to fund or decline it. Here is how to decide with discipline.
Why does the CBD versus THC distinction matter for funding?
The CBD versus THC funding decision is the first split a claims team should make, because the two cannabinoids carry very different risk. CBD (cannabidiol) is non-intoxicating, usually supplied as an oil, generally safe to drive on, and has a favourable side-effect profile with low impact on return to work and functioning.
THC (tetrahydrocannabinol) is the active, psychoactive component that binds CB1 receptors. It is the source of almost all the risk that matters on a claim: side effects, driving and functional impairment, and barriers to return to work. A CBD approval is not a THC approval, and a request for THC should be treated as the higher-risk decision it is.
What is the approval trap, and how do you avoid it?
A recurring problem is the approval mismatch. An insurer approves funding for CBD, then the prescriber supplies a range of THC-containing products instead. Early blanket responses such as "medicinal cannabis is now approved" were read by prescribers as permission to supply any cannabis product. Approving a whole class rather than a specific product is the equivalent of approving "opioids" with no product limit.
Scale makes this harder. Close to 1,500 registered products are available in Australia, with more released continually, and registered is not the same as TGA approved. Patients are rarely on a single product. It is common to see four or five different flowers, sativa and indica, day and night formulations, and varying THC strengths used at different times of day.
Why do vape pens cause silent dose escalation?
THC vape pen dose escalation is a newer and easily missed pattern. A THC vape pen is a concentrated THC oil inhaled like a nicotine vape, distinct from flower used with a vaporiser. Because it is straight THC oil without the moderating terpenes and other cannabinoids found in whole flower, a vape pen delivers roughly six times the THC strength of flower.
| Form | Relative THC strength | Claim risk |
|---|---|---|
| Cannabis flower (vaporised) | Baseline | Moderated by terpenes and other cannabinoids |
| THC vape pen (oil) | Around six times flower | Hidden dose jump, often unflagged |
A patient transitioning from flower to a vape pen can unknowingly multiply their effective dose. The effect differs, and the escalation often goes unrecorded on the claim, which is why a transition from flower to pen should be flagged for review.
Who is prescribing, and why does it raise governance risk?
Isolated and dedicated cannabis practices are prescribing at volume, increasingly through online-only telehealth models, and pharmacies are now dispensing cannabis directly. Nurse practitioners can prescribe via the Special Access Scheme without doctor oversight, within their authorised scope, and regulators expect thorough assessment, monitoring and communication with the patient's usual GP.
Regulators have identified doctors issuing up to 100 prescriptions in a single day, about one every four minutes. These models are linked to limited clinical oversight, poor coordination with the usual GP, assessment based largely on self-reported conditions, and rising access to high-strength THC. AHPRA is actively investigating high-volume prescribing and tightening telehealth rules, treating script-only or minimal-contact prescribing as non-compliant, and some current clinic models may face enforcement.
What does the clinical evidence on medicinal cannabis actually show?
For psychological conditions, no meaningful benefit has been demonstrated in high-quality trials, and there is no randomised controlled trial evidence for depression. Much of the research is low certainty and high risk of bias. There are higher adverse-effect rates than placebo, a risk of increased craving in substance use disorders, and the prospect of delaying stronger evidence-based care such as CBT.
For chronic and neuropathic pain, only about one in 22 to 26 patients achieve meaningful (30 to 50 percent) pain reduction in chronic non-cancer pain. There is moderate evidence for small gains in some neuropathic pain, but it is insufficient for arthritis or fibromyalgia, with no consistent quality-of-life gain and higher rates of dizziness, drowsiness and cognitive impairment. Cannabis is not first-line care and, at most, a monitored adjunct in selected patients.
How should insurers approach medicinal cannabis funding decisions in personal injury claims?
Medicinal cannabis funding decisions are most defensible when they rest on a conditional approval process supported by a pharmacist-led medication review. This anchors the decision in evidence and in the specific product, separates CBD from THC, and creates a documented basis for funding while the funding question remains legislatively unsettled across the states.
In practice this means approving named products rather than classes, treating THC as the higher-risk request, flagging dose escalation and vape pen transitions, and scrutinising the prescribing model where high-volume online prescribing or weak GP coordination is present.
Key Takeaways
- Approve named products, not the whole class, and specify the product, cannabinoid and strength on every approval.
- A CBD approval is not a THC approval, so treat THC as the higher-risk decision.
- Flag any transition from flower to a vape pen as a roughly sixfold strength increase that warrants review.
- High-volume online or telehealth prescribing with weak GP coordination is a governance and enforcement risk.
- The evidence is weak for psychological conditions and modest for pain, so cannabis should not displace established therapies.
- A conditional approval supported by a pharmacist review gives a defensible basis while state funding rules remain unsettled.
Frequently Asked Questions
Does approving CBD mean we have approved THC as well?
No. A CBD approval is not a THC approval. Name the specific product, cannabinoid and strength on every approval, and treat any THC request as a separate, higher-risk decision.
Why does a switch from cannabis flower to a vape pen matter?
A THC vape pen delivers roughly six times the strength of flower because it is straight THC oil. A patient moving from flower to a pen can multiply their effective dose without it being flagged on the claim.
Is medicinal cannabis supported by strong clinical evidence?
Not for most claims. There is no randomised controlled trial evidence for depression, and only about one in 22 people with chronic non-cancer pain achieve meaningful pain reduction. Cannabis is not first-line care.
How can claims teams fund medicinal cannabis defensibly?
Use a conditional approval process supported by an independent pharmacist review. This gives a documented, evidence-anchored basis for the decision while the funding question remains legislatively unsettled across the states.
Primary source: Therapeutic Goods Administration (TGA) medicinal cannabis access and product registration guidance, and AHPRA prescribing compliance updates, 2026.
